Financial Performance Highlights
Godrej Agrovet achieved record consolidated revenue of ₹10,232.68 crore in FY26, representing 9.1% growth from ₹9,382.77 crore in FY25. Net profit attributable to owners increased by 10.0% to ₹472.78 crore from ₹429.72 crore. Key profitability metrics showed improvement with Return on Capital Employed reaching 20% compared to 16% in the previous year. The company maintained strong segment performance across Animal Nutrition (₹4,930 crore revenue), Vegetable Oil (₹1,999 crore), Crop Care (₹1,174 crore), Dairy (₹1,584 crore), and Poultry/processed food (₹767 crore).
Annual General Meeting Details
The 35th AGM will be held virtually on August 5, 2026 at 4:00 PM IST via video conferencing. Key resolutions include adoption of FY26 financial statements, declaration of 110% final dividend (₹11 per equity share), re-appointment of directors including Ms. Nisaba Godrej and Mr. Pirojsha Godrej, and approval of remuneration for Mr. Burjis Godrej as Chairperson & Executive Director. Remote e-voting will be available from August 1-4, 2026, with book closure from July 30 to August 4 for dividend eligibility.
Corporate Governance and Management Changes
The Board comprised 12 Directors with proper composition of independent directors. Significant management changes included Mr. Balram Singh Yadav's retirement as Managing Director and appointment of Mr. Sunil Kataria as CEO & Managing Director effective September 1, 2025. Director remuneration totaled ₹108.39 lakhs for non-executive directors, while executive compensation included ₹8.4 crore for Mr. Yadav and ₹9.7 crore for Mr. Kataria. All committees (Audit, Nomination, Stakeholders, Risk, CSR) maintained regulatory compliance with regular meetings throughout the year.
Strategic Investments and Acquisitions
The company completed significant strategic moves including acquiring an additional 37.25% stake in Creamline Dairy Products Limited for ₹717.51 crore, increasing holding to 99.78%. Participation in Astec LifeSciences Limited's rights issue of ₹249.35 crore raised ownership to 67.03% from 64.75%. Godrej Foods Limited became a wholly owned subsidiary after acquiring the remaining 49% stake. Investments in subsidiaries totaled ₹572.90 crore in Astec LifeSciences and ₹1,084.08 crore in Creamline Dairy.
Financial Position and Balance Sheet
Standalone financials showed property, plant and equipment of ₹1,825.48 crore gross block with net block of ₹1,050.96 crore. Biological assets including oil palm saplings were valued at ₹52.98 crore. Consolidated borrowings increased to ₹1,468.43 crore with adjusted net debt-to-equity ratio of 0.54. Supplier financing arrangements expanded to ₹968.67 crore. Employee benefit expenses rose to ₹635.15 crore including ₹30.44 crore exceptional item for new labor code provisions.
Compliance and Regulatory Matters
The company received an administrative warning from SEBI dated September 29, 2025 for delayed disclosures under SAST Regulations regarding Astec Lifesciences acquisitions made in 2017-2020. Otherwise, the company maintained full compliance with Companies Act, 2013, SEBI LODR Regulations, and Secretarial Standards. Contingent liabilities totaled ₹164.76 crore including GST demands, income tax disputes, and other claims.
Dividend and Capital Management
The Board recommended a final dividend of ₹11 per fully paid equity share (110% on face value of ₹10), subject to shareholder approval at the AGM. Total dividend payout is approximately ₹211.56 crore. The record date for dividend eligibility is July 29, 2026, with payment scheduled for August 10, 2026. Capital management focused on maintaining optimal debt-equity structure while funding strategic growth initiatives.
Signatories and Assurance
The financial statements were approved by Chairman N. B. Godrej, CEO Sunil Kataria, CFO S. Varadaraj, and Company Secretary Vivek Raizada. Audit was conducted by B S R & Co. LLP with partner Maulik Jhaveri. The company confirmed compliance with all applicable accounting standards (Ind AS) and regulatory requirements, providing comprehensive disclosures across all reportable segments and business operations.